-->

Rosellini Scientific Acquires Remote Monitoring Portfolio from Medtronic

The patents, which relate to remote monitoring of implantable medical devices, will be developed in companies spun-out of Rosellini Scientific, all of whom will have a focus on enhancing the delivery of digital medicine at the point of care.

Dallas, Texas (PRWEB) March 09, 2014 – Rosellini Scientific, Inc. announced today that it has acquired a medical device portfolio from Medtronic consisting of six U.S. and eight International patents. The patents, which relate to remote monitoring of implantable medical devices, will be developed in companies spun-out of Rosellini Scientific, all of whom will have a focus on enhancing the delivery of digital medicine at the point of care. This includes combinations of remote monitoring and treatment, hospital inventory management and electronic medical record integration.

Commenting on the announcement, VP of Emerging Therapies Austin Duke, Ph.D., stated, “We will continue to focus on building a diversified portfolio of compelling patent assets in the implantable device space. Therapy is going to become more patient-centric and will increasingly be delivered point-of-care, as opposed to the confines of the large hospitals. We expect our product development path to continue to focus on smart, networked, implantable devices that change the standard of care in post-acute settings.”

The Company has recently formed CardiaX, Inc. to develop the CardioPT™ device, which will serve as a comprehensive solution for patients with advanced heart failure, atrial fibrillation, and ventricular arrhythmias leading to sudden cardiac death. The technology has received nearly $2 million in development funding.

About Rosellini Scientific
Our focus begins in the hospital bed and follows the patient through their continuum of care. We support patients by preventing disease, restoring function and enhancing the quality of life. Our goal is to manage the medical devices designed to support patients in sub-acute healthcare settings. Where devices do not already exist, we invent them by developing solutions utilizing the interconnection of software, hardware and biomedical implants. Visit http://www.roselliniscientific.com for more information.

Electric Stimulator Guides Neuroplasticity to Treat Tinnitus

MedGadget, Mar 7, 2014 • 12:43 pm

Electric Stimulator Guides Neuroplasticity to Treat Tinnitus (VIDEO)

Tinnitus is a debilitating condition thought to be caused by the brain generating a signal in areas no longer stimulated by the auditory system. The brain’s natural plasticity can potentially be utilized to treat tinnitus, by stimulating adjacent regions of the brain. A new system that works on the auditory cortex to guide neuroplasticity has been developed by MicroTransponder, a spin-off company from University of Texas at Dallas (UTD), and the technology is now set to begin clinical trials.

Serenity System couples an implantable vagus nerve stimulator with a tone generator that plays sounds of various frequencies while electric signals are delivered by the neurostimulator.

The Serenity System couples an implantable vagus nerve stimulator with a tone generator that plays sounds of various frequencies while electric signals are delivered by the neurostimulator. Stimulating the vagus nerve releases chemicals involved in neuroplasticity, so doing so while playing the tones will hopefully train the brain to correlate the various sound frequencies to their normal areas in the auditory cortex.

View full article with video.

NIH Launches ‘Nerve Stimulation’ Trial to Ease Tinnitus

By Robert Preidt, HealthDay Reporter

THURSDAY, March 6, 2014 (HealthDay News) — Volunteers are being recruited for a clinical trial to test a new method to treat ringing in the ears, the troubling condition known as tinnitus.

ear_SS36021.jpg

The technique being studied uses nervous system stimulation to “rewire” parts of the brain in an attempt to significantly reduce or eliminate tinnitus. If it proves successful, it could offer hope to millions of Americans with the disorder, according to the U.S. National Institute on Deafness and Other Communication Disorders (NIDCD), which is funding the study.

“Tinnitus affects nearly 24 million adult Americans,” NIDCD director Dr. James Battey Jr. said in a government news release. “It is also the number one service-connected disability for returning veterans from Iraq and Afghanistan. The kind of nervous system stimuli used in this study has already been shown to safely and effectively help people with epilepsy or depression. This therapy could offer a profoundly better way to treat tinnitus.”

During therapy, patients hear a series of single-frequency tones through headphones. At the same time, stimulation is delivered to the vagus nerve, which runs from the head and neck to the abdomen. When stimulated, the vagus nerve releases chemicals that can rewire the brain, the researchers explained in the news release.

Previous studies in rats and humans suggested that vagus nerve stimulation could be effective in reducing or eliminating tinnitus, according to the NIDCD.

The new clinical trial will include adults who have had moderate-to-severe tinnitus for at least a year. They will undergo daily 2.5-hour sessions of vagus-nerve stimulation and audio-tone therapy over six weeks.

The trial will be conducted at four centers through an agreement with a Dallas-based medical device company called MicroTransponder, Inc. The centers include the University of Texas at Dallas, University at Buffalo in New York and the University of Iowa. A fourth center will be announced later this year.

“This trial has the potential to open up a whole new world of tinnitus management,” Dr. Gordon Hughes, director of clinical trials at the NIDCD, said in the news release.

“Currently, we usually offer patients a hearing aid if they have hearing loss or a masking device if they don’t,” Hughes said. “None of these treatments cures tinnitus. But this new treatment offers the possibility of reducing or eliminating the bothersome perception of tinnitus in some patients.”

More information

The American Academy of Otolaryngology — Head and Neck Surgery has more about tinnitus.

TONES: The Headband that Relieves Migraines

Rosellini Scientific is partnering with NeuroTek Medical to develop a non-invasive device that uses electrical impulses to relieve migraine pain. The TONES (Transcutaneous Occipital Nerve Electrical Stimulation) project was recently selected to compete for the EDF Pulse “Electricity and Smart Living” Awards, which recognizes innovations that improve the quality of daily life. If the project wins the competition, we will receive a financial award to further the development of the device, as well as a high-profile visibility and communication campaign to market the device to migraineurs who desperately need pain relief.


Visit http://pulse.edf.com/en/tones-headband-relieves-migraines/ and click on the links to share via social media. Feel free to leave comments as well! Winners are chosen by voting and social media, so please share and comment if you like what we’re working on. We have a tremendous product that can potentially improve the quality of life for so many people around the world.


The EDF Pulse Awards recognize companies who are helping solve some of the world’s most important issues and in innovative ways.


The tiny brain trainer that helps get you moving after a stroke

by Carol Davis

Around 150,000 Britons a year suffer a stroke. Mikey Cousland, 42, a taxi driver from West Lothian, Scotland, had one last year and underwent a new procedure to help him recover movement in his arm, as he tells Carol Davis.

THE PATIENT

After driving my taxi around Edinburgh one Sunday in May 2012, I went to fitness training and then to my granddaughter Mya’s first birthday party. I fell into bed, exhausted. My next shift was due to start at 4am.

But when my wife Tracey woke at 5am, I was still asleep. She shook me to wake me up, but no matter how hard I tried, I couldn’t get up – my right leg was numb. Nor could I move my right arm or hand, and I couldn’t speak. I’d try to move my mouth but couldn’t think of the words. It was terrifying. I had tests at Forth Valley Royal Hospital in Larbert, including an MRI scan of my brain, and was told I’d had a stroke. I was shocked – I was fit with no risk factors such as a family history or smoking.

I spent three months in hospital, doing physiotherapy to learn to use my body again. But I was still left in a wheelchair and could barely speak above a whisper. My right arm hung uselessly, supported by a sling. Luckily, I’m left-handed, so I could feed myself. Over three or four weeks, I learned to walk again using a stick, and had speech therapy and physiotherapy. But my right hand was next to useless – I could move my fingers but barely raise my hand. The physiotherapist said to keep trying to move it so my brain could learn new pathways. I still couldn’t form words, so I’d point to things to communicate with Tracey. She stopped work as a taxi driver to become my carer. She even had to dress me.

After my speech therapist told me about a trial of a new device that could help, I saw Dr Jesse Dawson at the Western Infirmary in Glasgow in July. He asked me to lift a tiny ball bearing and a marble to test my strength and dexterity, but I struggled and dropped them. Even lifting a baseball cap from the table was difficult.

Dr Dawson told me a nerve stimulator would be fitted around my vagus nerve, which runs from the brain to the abdomen. The stimulator (the size of a matchbox) would be implanted in my chest and linked to an electrode wrapped around the nerve in my neck. It sends electrical signals to activate the nerve to prompt my brain to release more chemical messengers (neurotransmitters) that help make connections in the brain. The stimulator would be fired while doing my arm rehabilitation exercises and would hopefully retrain my brain to do the actions.

The one-hour operation took place in August under general anaesthetic and I left the next day with dressings on my neck and chest. I had six weeks of physiotherapy, when doctors fired the stimulator using a remote control. At first, I struggled to reach a bottle on the table, but after a few weeks I could do it. It was like magic.

When the stimulator was on, I felt an odd tickle in my throat but it didn’t hurt. Week by week, I improved. Gradually, I could lift a baseball cap above my shoulder, and pass a newspaper from my damaged right hand to my left. Doctors can’t say for sure if it is due to the stimulator, though. Now I only use a stick on long walks, I can drink tea and dress myself again. It’s been a long haul, but I’ve been told I should keep improving – and by next year I hope to be driving again.

Read more

Materials Scientist’s Research Contributes To Invention Recognized by Time Magazine

Professor Co-Developed Film That Enables Microchip Implantation Inside Eye 

A device created by an interdisciplinary group of researchers, including a UT Dallas professor, was recently named one of the best inventions of 2013 by Time magazine.

Dr. Orlando Auciello

Dr. Orlando Auciello, a professor in the Erik Jonsson School of Engineering and Computer Science, helped develop a way to protect microchips from saline in the human eye.

The Argus II Retinal Prosthesis System restores partial vision to people blind from eye diseases such as retinitis pigmentosa and macular degeneration. It earned recognition as one of the 25 Best Inventions of the Year 2013 in the Nov. 25 edition of Time. It is one of five inventions featured in the accompanying video available on the magazine’s website.

The device was developed by a group of researchers from five national laboratories, four universities and Second Sight Medical Products. Dr. Orlando Auciello, an endowed chair professor of materials science and engineering and bioengineering in the Erik Jonsson School of Engineering and Computer Science, was part of the team from Argonne National Laboratory that worked on the device.

While at Argonne, Auciello worked on the fundamental and applied research to develop a special coating now known as ultrananocrystalline diamond (UNCD) film that protects the silicon microchip from being attacked by the saline in the eye. Without the layer of protection, the saline would destroy the microchip.

Continue reading

Clinical Trial Brings Positive Results for Tinnitus Sufferers

UT Dallas researchers have demonstrated that treating tinnitus, or ringing in the ears, using vagus nerve stimulation-tone therapy is safe and brought significant improvement to some of the participants in a small clinical trial.

Drs. Sven Vanneste and Michael Kilgard of the School of Behavioral and Brain Sciences used a new method pairing vagus nerve stimulation (VNS) with auditory tones to alleviate the symptoms of chronic tinnitus. Their results were published on Nov.  20 in the journal Neuromodulation: Technology at the Neural Interface.

VNS is an FDA-approved method for treating various illnesses, including depression and epilepsy. It involves sending a mild electric pulse through the vagus nerve, which relays information about the state of the body to the brain.

“The primary goal of the study was to evaluate safety of VNS-tone therapy in tinnitus patients,” Vanneste said. “VNS-tone therapy was expected to be safe because it requires less than 1 percent of the VNS approved by the FDA for the treatment of intractable epilepsy and depression. There were no significant adverse events in our study.”

According to Vanneste, more than 12 million Americans have tinnitus severe enough to seek medical attention, of which 2 million are so disabled that they cannot function normally. He said there has been no consistently effective treatment.

The study, which took place in Antwerp, Belgium, involved implanting 10 tinnitus sufferers with a stimulation electrode directly on the vagus nerve. They received 2 ½ hours of daily treatment for 20 days. The participants had lived with tinnitus for at least a year prior to participating in the study, and showed no benefit from previous audiological, drug or neuromodulation treatments. Electrical pulses were generated from an external device for this study, but future work could involve using internal generators, eliminating the need for clinical visits.

For the study, a stimulation electrode was implanted directly on the vagus nerve of 10 tinnitus sufferers. They received 2  hours of daily treatment for 20 days.

For the study, a stimulation electrode was implanted directly on the vagus nerve of 10 tinnitus sufferers. They received 2 ½ hours of daily treatment for 20 days.

Half of the participants demonstrated large decreases in their tinnitus symptoms, with three of them showing a 44-percent reduction in the impact of tinnitus on their daily lives. Four people demonstrated clinically meaningful reductions in the perceived loudness of their tinnitus by 26 decibels.

Five participants, all of whom were on medications for other problems, did not show significant changes. However, the four participants who benefited from the therapy were not using any medications. The report attributes drug interactions as blocking the effects of the VNS-tone therapy.

“In all, four of the 10 patients showed relevant decreases on tinnitus questionnaires and audiological measures,” Vanneste said. “The observation that these improvements were stable for more than two months after the end of the one month therapy is encouraging.”

Researchers at the University Hospital Antwerp, Belgium, and MicroTransponder Inc. also contributed to the study.

larger study involving four different centers will soon begin in the United States.

Media Contact: Ben Porter, UT Dallas, (972) 883-2193, ben.porter@utdallas.edu
or the Office of Media Relations, UT Dallas, (972) 883-2155, newscenter@utdallas.edu.

Rosellini Scientific Benelux SA Joins Walloon Region Consortium to Help Develop Implant System for Glaucoma Treatment

An exciting new medtech player in Belgium’s Walloon Region – Rosellini Scientific Benelux SA (RSB) – joins the consortium to develop a novel implant system for treating and monitoring glaucoma.

Rosellini Scientific Benelux SA Joins Walloon Region Consortium to Help Develop Implant System for Glaucoma Treatment - See more at: http://win-health.org/rosellini-scientific-benelux-sa-joins-walloon-region-consortium-to-help-develop-implant-system-for-glaucoma-treatment/#sthash.XBUW7wBB.dpuf

The 4-partner consortium, led by iSTAR Medical SA (Isnes, Belgium) – an ophthalmic implant company established in 2010, comprises iSTAR Medical, RSB, the Catholic University of Louvain (UCL) and the University of Liège (ULg).

The project – STARflo PLUS™ – will focus on developing a ‘next generation’ glaucoma management system designed to reduce and continuously monitor intraocular pressure (IOP) in patients suffering from glaucoma by combining biomaterials, biosensors and telemedicine technologies.

RSB, the Belgium-based subsidiary of Rosellini Scientific, LLC, will be developing the STARflo PLUS™ communication system to read and process data from miniature sensors implanted in the device.

BioWin, in coordination with Belgium’s Government of the Walloon Region, has provided approximately $5 million in funding for the new project, $1 million of which has been awarded to Rosellini Scientific Benelux. RSB will be Rosellini Scientific’s third spinout and first in Europe. In addition to the STARflo PLUS™ system, Rosellini Scientific Benelux will also develop technologies and applications that interface with the nervous system to treat a variety of diseases, including atrial fibrillation, overactive bladder and brain cancers.

“This is an exciting opportunity for Rosellini Scientific to partner with leading innovators in an environment that fosters cutting-edge medical technologies,” stated Hartmut Spitaels, President of Rosellini Scientific Benelux. “With this partnership, we can leverage our platform technology and benefit from an efficient pathway to clinical presence. We aim at starting trials with leading clinicians in Belgium and extending further distribution in the EU.”

Another exciting partnership worth keeping an eye on!

About Rosellini Scientific, LLC

Rosellini Scientific, LLC is an emerging leader in the development of implantable, wireless, electronic neurostimulation and implantable medical devices for the treatment of a variety of pathologies. The company and its founders have been a part of nearly $30 million in active implantable device development. Rosellini Scientific is currently developing therapeutic technologies for diverse applications including severe asthma, type 2 diabetes mellitus, painful diabetic peripheral neuropathy, overactive bladder and atrial fibrillation. RSB will be Rosellini Scientific’s third spinout and first in Europe. Rosellini Scientific previously spun-out MicroTransponder, Inc. in 2006, which developed wireless technology for the treatment of neurological disorders such as tinnitus and stroke. Large-scale, multi-center clinical trials of these devices, including a first-in-man clinical trial at the University of Antwerp, are ongoing. Visit http://roselliniscientific.com/ to learn more.

MicroTransponder Announces $3M in Funding, the First Patient Implant in a Stroke Clinical Trial, and Key Patent Issuance

MicroTransponder Announces $3M in Funding, the First Patient Implant in a Stroke Clinical Trial, and Key Patent Issuance

DALLAS, Texas – August 28, 2013 – MicroTransponder, Inc., (www.microtransponder.com) a privately-held medical device company has several announcements. The Company announced that it completed a $3.39 Million funding round this summer, which will enable the Company to complete 3 additional clinical trials using their neurostimulation system to treat both stroke patients and tinnitus patients and continue development of its wireless pain platform. This round of investment was led by Green Park & Golf Ventures, a Texas based healthcare investment firm. The round also included angel investors and the UT Horizon Fund.

“MicroTransponder’s VNS paired neurostimulation therapy has the potential to fundamentally change the standard of care for neurological disease,” states Dr. Clay Heighten, a founding partner of Green Park & Golf Ventures. “The MicroTransponder team is adept at translating neuroscience research into clinical therapies and we look forward to their efforts to improve the lives of millions of patients living with neurological disorders.”

Continue reading

Mad science: Developers turn to science to build a better apocalypse | Polygon

 

MadScience

Mad science: Developers turn to science to build a better apocalypse | Polygon.

Not every developer thinks scientific realism is worth bothering with, however. For example, Naughty Dog waves away the exact details of the fungal plague that destroyed humanity in The Last of Us. In Bethesda’s Fallout 3, much of world remains barren of life, even though in the 200 years since the nuclear apocalypse, topside ecosystems inevitably would have recovered. And, while Valve’s Portal is sometimes used to teach science, the Portal gun itself remains the stuff of engineering fantasy. That is, in many cases, developers decide beforehand the story they’d like to tell; scientific accuracy just gets in the way of the fun.

That’s fine, until the lack of good science begins to hurt the game’s narrative, says neuroscientist Will Rosellini.

“Gamers are getting older, and they expect smarter games,” says the Dallas, Texas-based CEO of MicroTransponder Inc. “What worked for them when they were 16 will just make them roll their eyes at 40.”

Rosellini was the consulting scientist for Eidos’ Deus Ex: Human Revolution, the latest in a series of games known for exploring the relationship between man and machine via the use of augmentation technologies, like with neural implants or prosthetics.

His contributions to the game include everything from “neuropozyne,” aka Nu-Poz, the highly addictive drug that prevents rejection of neural implants, to the voice-activated kill switch that could disable a character’s prosthetic limbs.

“All this could actually happen,” he says. “It was my job to do the research and figure out the how.”

Rosellini’s particular obsession with “the how” is ultimately what led him away from his former career path: playing pro ball with the Arizona Diamondbacks.

Continue reading.